Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?
Karam Khaddour, Michael Ansstas, John Visconti, George Ansstas
Topics & Concepts
NivolumabMedicineIpilimumabOlaparibImmune checkpointOncologyCancer researchInternal medicinePARP inhibitorImmunotherapyCancerPoly ADP ribose polymeraseBiologyBiochemistryPolymeraseGenePARP inhibition in cancer therapyCancer Immunotherapy and BiomarkersCAR-T cell therapy research